Buy Exemestane (Aromasin) online

Price: 983 UAH

Known as original brand(s)

Aromasin

Buy Exemestane (Aromasin) online with delivery. Browse medicines that contain Exemestane, compare doses and prices.

Exemestane is an irreversible, steroidal aromatase inactivator originally marketed under the brand name Aromasin. It is widely used in gynecologic oncology for the endocrine treatment of estrogen receptor-positive breast cancer in postmenopausal women.

The mechanism of action of exemestane involves covalent and irreversible binding to the substrate-binding site of the aromatase enzyme (which converts peripheral androgens to estrogens). This causes enzyme inactivation ("suicide inhibition") and reduces circulating estrogen levels by over 85–90%, depriving estrogen-dependent tumor cells of growth stimuli.

Clinical use of exemestane significantly reduces the risk of disease recurrence in adjuvant settings and controls tumor progression in advanced breast cancer stages.

Wikipedia page
Exemestane (Aromasin)

Indications

Exemestane is indicated in medical oncology for the following conditions:

  • Adjuvant Therapy: Adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer following 2 to 3 years of initial adjuvant tamoxifen therapy.
  • Advanced Breast Cancer: Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following antiestrogen therapy.

Dosage and administration

Exemestane is intended for oral administration in adult postmenopausal women:

  • Recommended Dosage: The standard dose is 25 mg (one tablet) taken once daily.
  • Administration Method: Tablets should be taken orally, preferably after a meal (food significantly enhances bioavailability).
  • Duration of Treatment: In early breast cancer, sequential adjuvant endocrine therapy (tamoxifen followed by exemestane) is continued for a total of 5 years or until disease relapse. In advanced disease, treatment continues until tumor progression.
  • Monitoring: Postmenopausal status should be biochemically confirmed (LH, FSH, estradiol levels) before initiating therapy in patients with uncertain menopausal status.

Exemestane is contraindicated in the following cases:

  • Premenopausal Status: Premenopausal endocrine status (women with active ovarian function).
  • Pregnancy and Lactation: Pregnancy and breastfeeding periods.
  • Hypersensitivity: Known hypersensitivity to exemestane or any formulation excipients.
  • Pediatric Use: Not indicated for pediatric use.

Exemestane is generally well tolerated, but the following adverse reactions may occur:

  • Vascular & Systemic: Hot flashes (very common), fatigue, asthenia, hyperhidrosis, and peripheral edema.
  • Musculoskeletal: Arthralgia, myalgia, pain in extremities, and decreased bone mineral density (increased risk of osteoporosis and fractures).
  • Nervous System: Headache, insomnia, depression, dizziness, and carpal tunnel syndrome.
  • Gastrointestinal: Nausea, abdominal pain, vomiting, diarrhea, and elevated liver enzymes.
  • Dermatologic: Rash and alopecia.

Frequently Asked Questions

Exemestane is an oral antineoplastic agent classified as a steroidal aromatase inhibitor. Structurally related to the natural substrate androstedione, exemestane acts as a suicide inactivator by irreversibly binding to the active site of the aromatase enzyme, which converts circulating androgens into estrogens in peripheral tissues. By permanently inactivating the enzyme, exemestane suppresses plasma estrogen levels by over 90%, depriving hormone-sensitive breast cancer cells of the estrogenic stimulation required for growth.
Exemestane is indicated for the treatment of hormone receptor-positive (HR+) early or advanced breast cancer in postmenopausal women (whether natural or medically induced). It is widely utilized as adjuvant therapy, including sequential therapy following 2 to 3 years of tamoxifen, as well as for advanced disease that has progressed following prior anti-estrogen or non-steroidal aromatase inhibitor therapies (such as anastrozole or letrozole).
The standard recommended dosage of exemestane is 25 mg (one tablet) taken once daily. The tablet should be swallowed whole at approximately the same time each day, preferably after a meal. Administering exemestane following food significantly enhances its systemic absorption, increasing plasma drug bioavailability by approximately 40% compared to administration under fasting conditions. The total duration of treatment is guided by the oncologist, typically ranging from 2 to 5 years.
Profound estrogen deprivation induced by exemestane leads to a accelerated reduction in bone mineral density, increasing the long-term risk of osteopenia, osteoporosis, and fragility fractures. Patients should undergo baseline dual-energy X-ray absorptiometry (DEXA) scanning prior to initiating therapy, with follow-up scans every 1 to 2 years. To mitigate bone loss, routine supplementation with calcium and vitamin D is recommended, and antiresorptive agents such as bisphosphonates or denosumab may be prescribed if bone density decreases significantly.
The most frequently reported adverse effects of exemestane stem from estrogen deprivation and include hot flashes, hyperhidrosis, fatigue, insomnia, headache, arthralgia (joint pain), and myalgia. Musculoskeletal stiffness and joint discomfort are classic class-effects of aromatase inhibitors. Most symptoms are mild to moderate in severity. Management strategies for persistent arthralgia include regular low-impact exercise, physical therapy, or mild non-opioid analgesics.

Medicines containing Exemestane

-15%
Xtane
View
Natco

Xtane

Exemestane
25 mg 30 tablets
983₴ 1162₴
✅ All products loaded (1)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00